BIIB up +1.23% percent Today $BIIB High is at 306.
Post# of 72711
Posted On: 11/18/2014 10:57:14 AM
BIIB up +1.23% percent Today $BIIB High is at 306.98 and the Low 304.08 with current volume of 449,456.
Recent News posted below.
Biogen Idec Inc BIIB other info.
http://investorshangout.com/Biogen-Idec-Inc-BIIB-53494/
BIIB Biogen Idec Inc Recent Headline News
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Surges 38.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 1 hr 31 mins ago
Sunesis (SNSS) was a big mover last session, with shares surging over 38% on the day.
BIIB: 305.61 (+3.19), SNSS: 2.22 (-0.09), AMAG: 35.73 (+0.97), AFFX: 9.50 (+0.21)
Forward Pharma Sues Biogen Idec Over Tecfidera(R) Sales in Germany
GlobeNewswire - 2 hrs 14 mins ago
Forward Pharma A/S (Nasdaq:FWP) announced today that it has filed a lawsuit against Biogen Idec GmbH, Biogen Idec International GmbH and Biogen Idec Ltd. in the Regional Court in Dusseldorf, alleging infringement of its German utility model DE 20 2005 022 112 due to Biogen Idec's marketing of Tecfidera(R) in Germany. With this lawsuit Forward Pharma ("the Company"
does not seek to stop sales of Tecfidera(R) to MS patients, but rather seeks damages for what the Company believes are Biogen Idec's unlawful sales of Tecfidera(R) in Germany.
BIIB: 305.61 (+3.19), FWP: 21.91 (+0.19)
Cramer's Lightning Round - Mobileye Will Have A Good Quarter (11/17/14)
SA Editor Miriam Metzinger - Seeking Alpha - Tue Nov 18, 5:40AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday November 17. Bullish Calls: Mobileye (NYSE: MBLY ) : "It has come down. I do feel it could have a good quarter. It has had a good run, there...
MACK: 8.82 (+0.20), DSX: 7.85 (+0.03), BIIB: 305.61 (+3.19), GE: 26.82 (+0.21), ALNY: 91.12 (+2.14), JCP: 7.28 (+0.02), MBLY: 47.38 (+0.40)
'Mad Money' Lightning Round: I'm Buy, Buy, Buying Biogen
at The Street - Tue Nov 18, 5:00AM CST
Cramer's not recommending J.C. Penney, likes Alnylam Pharmaceuticals and thinks GE is getting better.
MACK: 8.82 (+0.20), DSX: 7.85 (+0.03), BIIB: 305.65 (+3.23), GE: 26.82 (+0.21), ALNY: 91.12 (+2.14), JCP: 7.28 (+0.02), MBLY: 47.38 (+0.40)
Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us
at The Street - Mon Nov 17, 7:09PM CST
Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.
CST: 42.71 (+0.80), BIIB: 305.65 (+3.23), GE: 26.82 (+0.21), NKE: 95.84 (-0.22), HAL: 49.66 (+0.43), TSN: 42.57 (-0.46), GSAT: 2.63 (-0.17), LULU: 45.20 (+0.78), AGN: 212.06 (+2.86), MACK: 8.82 (+0.20), WHR: 177.35 (+1.80), UA: 68.94 (+0.05), DSX: 7.85 (+0.03), ALNY: 91.12 (+2.14), MPC: 92.64 (+0.13), JCP: 7.28 (+0.02), SHW: 240.60 (+1.29), MBLY: 47.38 (+0.40), REGN: 409.68 (+10.03), BHI: 65.85 (+0.62)
Alnylam Reports Positive Initial Phase II Data on Revusiran - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:40PM CST
Alnylam (ALNY) announced positive results of up to 98.2% knockdown of serum TTR in a phase II study on revusiran in TTR cardiac amyloidosis patients.
BIIB: 305.65 (+3.23), ALNY: 91.12 (+2.14), AMAG: 35.71 (+0.95), SNY: 48.23 (+0.69)
Is Mallinckrodt (MNK) Poised to Beat Q4 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 4:30PM CST
Mallinckrodt plc (MNK) is set to report fourth-quarter fiscal 2014 results on Nov 19.
IPXL: 29.25 (+0.54), MNK: 88.54 (+0.11), BIIB: 305.65 (+3.23), MYL: 56.16 (+1.03)
Sanofi's Lemtrada Gets U.S. Approval, Carries Boxed Warning - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 4:20PM CST
Sanofi's (SNY) Lemtrada has finally gained FDA approval for the treatment of patients suffering from relapsing forms of MS.
BIIB: 305.65 (+3.23), SNY: 48.23 (+0.69), NVS: 95.45 (+1.07)
Puma Biotechnology Falls on Disappointing Neratinib Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 1:04PM CST
Puma Biotechnology, Inc.'s (PBYI) neratinib failed to show significant improvement in progression free survival (PFS) as a first-line treatment of HER2-positive breast cancer.
BIIB: 305.65 (+3.23), PFE: 30.49 (+0.17), PBYI: 217.60 (+6.05)
Gilead Has Been Rocked After Earnings, But I'm Looking To Buy!
Abba's Aces - at Seeking Alpha - Mon Nov 17, 11:35AM CST
BIIB: 305.65 (+3.23), GILD: 102.03 (+1.59), INCY: 70.05 (+0.35), ALXN: 190.28 (+3.50), CELG: 106.45 (+2.09)
Kite Pharma's Q3 Loss Narrows Y/Y, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:42AM CST
Kite Pharma, Inc. (KITE) reported third-quarter 2014 loss of $0.24 per share well below the year-ago loss of $37 cents per share.
BIIB: 305.65 (+3.23), KITE: 40.08 (-0.22), ANIP: 54.03 (+1.16), AMAG: 35.71 (+0.95)
Stock Market News for November 17, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:10AM CST
Benchmarks finished almost flat on Friday as Eurozone’s soft GDP data offset encouraging economic reports
DHI: 24.49 (unch), HAS: 55.95 (-0.42), BIIB: 305.65 (+3.23), VRTX: 110.77 (-0.85), HAL: 49.67 (+0.44), M: 61.08 (-0.53), WMT: 83.64 (+0.07), SLB: 95.14 (-0.49), COG: 33.35 (-0.18), GILD: 102.03 (+1.59), EOG: 96.42 (+0.07), ALXN: 190.24 (+3.46), MRO: 31.73 (-0.09), CSCO: 26.54 (+0.07), BHI: 65.87 (+0.64)
Strength Seen in Geron (GERN): Stock Surges 19.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:25AM CST
Geron (GERN) was a big mover last session, with shares surging over 19% on the day.
BIIB: 305.65 (+3.23), GERN: 3.08 (+0.10), ILMN: 189.48 (+6.57), AFFX: 9.50 (+0.21)
Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:13PM CST
On Nov 14, 2014, Zacks Investment Research upgraded Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
BIIB: 305.65 (+3.23), ANIP: 54.03 (+1.16), AMAG: 35.71 (+0.95), AFFX: 9.50 (+0.21)
Geron Collaborates with J&J for Imetelstat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:00PM CST
Geron Corporation (GERN), a clinical-stage biopharmaceutical company, announced that it has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc., a unit of Johnson & Johnson (JNJ).
BIIB: 305.65 (+3.23), JNJ: 108.97 (+0.67), GERN: 3.08 (+0.10), AFFX: 9.50 (+0.21)
Biogen Idec Falls 3.95% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Nov 14, 3:42PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $300.35 to a high of $318.02. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $314.33 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 305.65 (+3.23)
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 3.95%
Comtex SmarTrend(R) - Fri Nov 14, 3:42PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $300.35 to a high of $318.02. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $314.33 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 305.65 (+3.23)
Isis/AstraZeneca Expand Antisense Technology Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 3:30PM CST
Isis Pharmaceuticals (ISIS) and AstraZeneca will co-develop targeted oligonucleotide delivery methods under the expanded collaboration.
BIIB: 305.65 (+3.23), ISIS: 49.98 (+0.97), AZN: 73.37 (+0.87), SNY: 48.23 (+0.69)
Mallinckrodt Shares Down on Setback for Generic Concerta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:39PM CST
Mallinckrodt (MNK) received a setback when the FDA informed the company that its methylphenidate hydrochloride extended-release tablets, USP (CII) might not be therapeutically equivalent to Johnson & Johnson's (JNJ) Concerta.
MNK: 88.54 (+0.11), BIIB: 305.65 (+3.23), JNJ: 108.97 (+0.67), ACT: 261.33 (+13.39)
Stocks Drift Lower As Biotechs Tumble
at Investor's Business Daily - Fri Nov 14, 1:48PM CST
Stocks drifted mostly lower Friday with a little more than one hour left in the session, with medical stocks leading the way down. Volume in the stock market today was running lighter than Thursday's levels. The Nasdaq rose less than 0.1%, the S&P...
BIIB: 305.65 (+3.23), NTES: 100.03 (-1.09), HAL: 49.68 (+0.45), BITA: 93.18 (+3.80), BHI: 65.90 (+0.67), CELG: 106.49 (+2.13)
Recent News posted below.
Biogen Idec Inc BIIB other info.
http://investorshangout.com/Biogen-Idec-Inc-BIIB-53494/
BIIB Biogen Idec Inc Recent Headline News
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Surges 38.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 1 hr 31 mins ago
Sunesis (SNSS) was a big mover last session, with shares surging over 38% on the day.
BIIB: 305.61 (+3.19), SNSS: 2.22 (-0.09), AMAG: 35.73 (+0.97), AFFX: 9.50 (+0.21)
Forward Pharma Sues Biogen Idec Over Tecfidera(R) Sales in Germany
GlobeNewswire - 2 hrs 14 mins ago
Forward Pharma A/S (Nasdaq:FWP) announced today that it has filed a lawsuit against Biogen Idec GmbH, Biogen Idec International GmbH and Biogen Idec Ltd. in the Regional Court in Dusseldorf, alleging infringement of its German utility model DE 20 2005 022 112 due to Biogen Idec's marketing of Tecfidera(R) in Germany. With this lawsuit Forward Pharma ("the Company"
does not seek to stop sales of Tecfidera(R) to MS patients, but rather seeks damages for what the Company believes are Biogen Idec's unlawful sales of Tecfidera(R) in Germany. BIIB: 305.61 (+3.19), FWP: 21.91 (+0.19)
Cramer's Lightning Round - Mobileye Will Have A Good Quarter (11/17/14)
SA Editor Miriam Metzinger - Seeking Alpha - Tue Nov 18, 5:40AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday November 17. Bullish Calls: Mobileye (NYSE: MBLY ) : "It has come down. I do feel it could have a good quarter. It has had a good run, there...
MACK: 8.82 (+0.20), DSX: 7.85 (+0.03), BIIB: 305.61 (+3.19), GE: 26.82 (+0.21), ALNY: 91.12 (+2.14), JCP: 7.28 (+0.02), MBLY: 47.38 (+0.40)
'Mad Money' Lightning Round: I'm Buy, Buy, Buying Biogen
at The Street - Tue Nov 18, 5:00AM CST
Cramer's not recommending J.C. Penney, likes Alnylam Pharmaceuticals and thinks GE is getting better.
MACK: 8.82 (+0.20), DSX: 7.85 (+0.03), BIIB: 305.65 (+3.23), GE: 26.82 (+0.21), ALNY: 91.12 (+2.14), JCP: 7.28 (+0.02), MBLY: 47.38 (+0.40)
Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us
at The Street - Mon Nov 17, 7:09PM CST
Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.
CST: 42.71 (+0.80), BIIB: 305.65 (+3.23), GE: 26.82 (+0.21), NKE: 95.84 (-0.22), HAL: 49.66 (+0.43), TSN: 42.57 (-0.46), GSAT: 2.63 (-0.17), LULU: 45.20 (+0.78), AGN: 212.06 (+2.86), MACK: 8.82 (+0.20), WHR: 177.35 (+1.80), UA: 68.94 (+0.05), DSX: 7.85 (+0.03), ALNY: 91.12 (+2.14), MPC: 92.64 (+0.13), JCP: 7.28 (+0.02), SHW: 240.60 (+1.29), MBLY: 47.38 (+0.40), REGN: 409.68 (+10.03), BHI: 65.85 (+0.62)
Alnylam Reports Positive Initial Phase II Data on Revusiran - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:40PM CST
Alnylam (ALNY) announced positive results of up to 98.2% knockdown of serum TTR in a phase II study on revusiran in TTR cardiac amyloidosis patients.
BIIB: 305.65 (+3.23), ALNY: 91.12 (+2.14), AMAG: 35.71 (+0.95), SNY: 48.23 (+0.69)
Is Mallinckrodt (MNK) Poised to Beat Q4 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 4:30PM CST
Mallinckrodt plc (MNK) is set to report fourth-quarter fiscal 2014 results on Nov 19.
IPXL: 29.25 (+0.54), MNK: 88.54 (+0.11), BIIB: 305.65 (+3.23), MYL: 56.16 (+1.03)
Sanofi's Lemtrada Gets U.S. Approval, Carries Boxed Warning - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 4:20PM CST
Sanofi's (SNY) Lemtrada has finally gained FDA approval for the treatment of patients suffering from relapsing forms of MS.
BIIB: 305.65 (+3.23), SNY: 48.23 (+0.69), NVS: 95.45 (+1.07)
Puma Biotechnology Falls on Disappointing Neratinib Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 1:04PM CST
Puma Biotechnology, Inc.'s (PBYI) neratinib failed to show significant improvement in progression free survival (PFS) as a first-line treatment of HER2-positive breast cancer.
BIIB: 305.65 (+3.23), PFE: 30.49 (+0.17), PBYI: 217.60 (+6.05)
Gilead Has Been Rocked After Earnings, But I'm Looking To Buy!
Abba's Aces - at Seeking Alpha - Mon Nov 17, 11:35AM CST
BIIB: 305.65 (+3.23), GILD: 102.03 (+1.59), INCY: 70.05 (+0.35), ALXN: 190.28 (+3.50), CELG: 106.45 (+2.09)
Kite Pharma's Q3 Loss Narrows Y/Y, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:42AM CST
Kite Pharma, Inc. (KITE) reported third-quarter 2014 loss of $0.24 per share well below the year-ago loss of $37 cents per share.
BIIB: 305.65 (+3.23), KITE: 40.08 (-0.22), ANIP: 54.03 (+1.16), AMAG: 35.71 (+0.95)
Stock Market News for November 17, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:10AM CST
Benchmarks finished almost flat on Friday as Eurozone’s soft GDP data offset encouraging economic reports
DHI: 24.49 (unch), HAS: 55.95 (-0.42), BIIB: 305.65 (+3.23), VRTX: 110.77 (-0.85), HAL: 49.67 (+0.44), M: 61.08 (-0.53), WMT: 83.64 (+0.07), SLB: 95.14 (-0.49), COG: 33.35 (-0.18), GILD: 102.03 (+1.59), EOG: 96.42 (+0.07), ALXN: 190.24 (+3.46), MRO: 31.73 (-0.09), CSCO: 26.54 (+0.07), BHI: 65.87 (+0.64)
Strength Seen in Geron (GERN): Stock Surges 19.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:25AM CST
Geron (GERN) was a big mover last session, with shares surging over 19% on the day.
BIIB: 305.65 (+3.23), GERN: 3.08 (+0.10), ILMN: 189.48 (+6.57), AFFX: 9.50 (+0.21)
Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:13PM CST
On Nov 14, 2014, Zacks Investment Research upgraded Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
BIIB: 305.65 (+3.23), ANIP: 54.03 (+1.16), AMAG: 35.71 (+0.95), AFFX: 9.50 (+0.21)
Geron Collaborates with J&J for Imetelstat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:00PM CST
Geron Corporation (GERN), a clinical-stage biopharmaceutical company, announced that it has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc., a unit of Johnson & Johnson (JNJ).
BIIB: 305.65 (+3.23), JNJ: 108.97 (+0.67), GERN: 3.08 (+0.10), AFFX: 9.50 (+0.21)
Biogen Idec Falls 3.95% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Nov 14, 3:42PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $300.35 to a high of $318.02. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $314.33 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 305.65 (+3.23)
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 3.95%
Comtex SmarTrend(R) - Fri Nov 14, 3:42PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $300.35 to a high of $318.02. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $314.33 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 305.65 (+3.23)
Isis/AstraZeneca Expand Antisense Technology Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 3:30PM CST
Isis Pharmaceuticals (ISIS) and AstraZeneca will co-develop targeted oligonucleotide delivery methods under the expanded collaboration.
BIIB: 305.65 (+3.23), ISIS: 49.98 (+0.97), AZN: 73.37 (+0.87), SNY: 48.23 (+0.69)
Mallinckrodt Shares Down on Setback for Generic Concerta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:39PM CST
Mallinckrodt (MNK) received a setback when the FDA informed the company that its methylphenidate hydrochloride extended-release tablets, USP (CII) might not be therapeutically equivalent to Johnson & Johnson's (JNJ) Concerta.
MNK: 88.54 (+0.11), BIIB: 305.65 (+3.23), JNJ: 108.97 (+0.67), ACT: 261.33 (+13.39)
Stocks Drift Lower As Biotechs Tumble
at Investor's Business Daily - Fri Nov 14, 1:48PM CST
Stocks drifted mostly lower Friday with a little more than one hour left in the session, with medical stocks leading the way down. Volume in the stock market today was running lighter than Thursday's levels. The Nasdaq rose less than 0.1%, the S&P...
BIIB: 305.65 (+3.23), NTES: 100.03 (-1.09), HAL: 49.68 (+0.45), BITA: 93.18 (+3.80), BHI: 65.90 (+0.67), CELG: 106.49 (+2.13)
(0)
(0)Scroll down for more posts ▼